Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mindray revenues nearly double for Q3

This article was originally published in Clinica

Executive Summary

Shenzhen, China-based Mindray Medical International reported a 94% increase in total revenues for the third quarter of 2008, spurred by strong sales across its product range. The firm saw revenues from its main patient monitoring and life support products business more than double during the period to reach $68m, reflecting the impact of its acquisition of US company's Datascope in May, a transaction that transformed Mindray into a global player with direct sales channels in the US and distributors in Europe. Revenues from the Chinese company's other two business segments – in vitro diagnostic products and medical imaging systems – increased 42% (at $35m) and 52% (at $33m), respectively. Total group turnover was $146.5m. "Prudent expense control" and cost savings from its vertically-integrated R&D and manufacturing model helped the company achieve net profit of $34m, up 48% from the same quarter last year. Mindray reaffirmed its earnings outlook for the full-year 2008, which would be between $132-135m. However, it lowered its revenue guidance from $560-580m to $550-$560m, due to changes in the budgeted currency exchange rates for the second half of 2008 to reflect the strengthening US dollar.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel